Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMA 002: Metabolic effects of Lopinavir and Combivir in healthy subjects
NCT00192621Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Nov 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lopinavir + ritonavir and lamivudine + zidovudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by The Kirby Institute. Primary endpoint: Changes from baseline in genes related to mitochondrial and lipid metabolism in adipocytes at 6 weeks. Started Nov 2004; status: completed.
02
Drugs
lopinavir + ritonavirlamivudine + zidovudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00192621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192621.